An Open-label, Repeated-dose, Dose Escalation Study of the Safety and Effectiveness of SANGUINATE for the Treatment of Leg Ulcers in Adult Patients With Sickle Cell Disease

Trial Profile

An Open-label, Repeated-dose, Dose Escalation Study of the Safety and Effectiveness of SANGUINATE for the Treatment of Leg Ulcers in Adult Patients With Sickle Cell Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs PEG-haemoglobin carbon monoxide (Primary)
  • Indications Leg ulcer; Sickle cell anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Prolong Pharmaceuticals
  • Most Recent Events

    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
    • 24 Feb 2017 Status changed to completed.
    • 28 Apr 2016 Planned initiation date changed from 1 Jan 2016 to 1 Jan 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top